| Species |
Human |
| Protein Construction |
| His |
CD30 Ligand/TNFSF8 (Gln63-Asp234)
Accession # P32971 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CD30 Ligand/TNFSF8, His, Human at 5μg/ml (100μl/well) on the plate can bind Human CD30, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
20.7 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 30-50 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD30 ligand (CD30L)/TNFSF8 is a type II membrane protein belonging to the TNF superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. The protein is also constitutively expressed on granulocytes and medullary thymic epithelial cells.CD30L is a cytokine that binds to TNFRSF8/CD30. Induces proliferation of T-cells. |
| Synonyms |
CD153; CD30 Ligand; CD30L; CD30-L; CD30LGMGC138144; TNFSF8; CD30LG |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
